Trial Profile
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal haemorrhage; Retinal neovascularisation; Retinal oedema
- Focus Therapeutic Use
- Acronyms RRR study
- 01 Jan 2022 Results assessing the efficacy of a treat-and-extend strategy with intravitreal ranibizumab for radiation-related macular edema, published in the Graefes Archive for Clinical and Experimental Ophthalmology.
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.
- 09 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.